Entrada Therapeutics (TRDA) Change in Accured Expenses (2020 - 2026)

Entrada Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$6.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 9.03% year-over-year to -$6.0 million; the TTM figure through Mar 2026 stood at $4.2 million (up 445.73% YoY), while the FY2025 annual figure was $4.7 million, up 177.63% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$6.0 million, down from $2.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $6.9 million in Q3 2022, with the low at -$6.0 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $1.6 million (2024), against an average of $357176.5.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses sank 795.59% in 2023, then soared 605.88% in 2025.
• Entrada Therapeutics' Change in Accured Expenses stood at -$4.3 million in 2022, then surged by 145.03% to $2.0 million in 2023, then sank by 121.74% to -$425000.0 in 2024, then jumped by 605.88% to $2.2 million in 2025, then sank by 376.84% to -$6.0 million in 2026.
• Business Quant data shows TRDA's Change in Accured Expenses at -$6.0 million in Q1 2026, $2.2 million in Q4 2025, and $3.7 million in Q3 2025.